Clorazepate Dipotassium

CHEMBL2096631 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
408.9 g/mol
LogP
Phase
4

A benzodiazepine prodrug that is converted to active desmethyldiazepam in the stomach, providing anxiolytic, anticonvulsant, and sedative effects. It is used for anxiety disorders, alcohol withdrawal, and as an adjunct in partial seizure management.

Khối lượng phân tử

408,9200 g/mol

TPSA

82,60 Ų

Lĩnh vực điều trị

Cơ chế tác dụng

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-]

InChI

InChI=1S/C16H11ClN2O3.2K.H2O/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12;;;/h1-8,14H,(H,18,20)(H,21,22);;;1H2/q;2*+1;/p-2

Molecular Formula

C16H11ClK2N2O4

HBD / HBA

2 / 5

Liên kết có thể quay

1

Nguyên tử nặng

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A benzodiazepine prodrug that is converted to active desmethyldiazepam in the stomach, providing anxiolytic, anticonvulsant, and sedative effects. It is used for anxiety disorders, alcohol withdrawal, and as an adjunct in partial seizure management.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Clorazepate Dipotassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2096631. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 167305. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.